These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity. Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D Front Immunol; 2021; 12():719077. PubMed ID: 34394127 [TBL] [Abstract][Full Text] [Related]
48. A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2. Wang W; Wang S; Meng X; Zhao Y; Li N; Wang T; Feng N; Yan F; Xia X Antiviral Res; 2024 May; 225():105854. PubMed ID: 38447647 [TBL] [Abstract][Full Text] [Related]
49. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection. van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP Front Immunol; 2021; 12():781280. PubMed ID: 34987509 [TBL] [Abstract][Full Text] [Related]
50. A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures. Dinnon KH; Leist SR; Schäfer A; Edwards CE; Martinez DR; Montgomery SA; West A; Yount BL; Hou YJ; Adams LE; Gully KL; Brown AJ; Huang E; Bryant MD; Choong IC; Glenn JS; Gralinski LE; Sheahan TP; Baric RS bioRxiv; 2020 May; ():. PubMed ID: 32511406 [TBL] [Abstract][Full Text] [Related]
51. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration. Yang Q; Hughes TA; Kelkar A; Yu X; Cheng K; Park S; Huang WC; Lovell JF; Neelamegham S Elife; 2020 Oct; 9():. PubMed ID: 33103998 [TBL] [Abstract][Full Text] [Related]
52. COVID-19 spike polypeptide vaccine reduces the pathogenesis and viral infection in a mouse model of SARS-CoV-2. Hisham Y; Seo SM; Kim S; Shim S; Hwang J; Yoo ES; Kim NW; Song CS; Jhun H; Park HY; Lee Y; Shin KC; Han SY; Seong JK; Choi YK; Kim S Front Immunol; 2023; 14():1098461. PubMed ID: 36936979 [TBL] [Abstract][Full Text] [Related]
53. Diosmetin-7-O-β-D-glucopyranoside from Pogostemonis Herba alleviated SARS-CoV-2-induced pneumonia by reshaping macrophage polarization and limiting viral replication. Xu YL; Li XJ; Cai W; Yu WY; Chen J; Lee Q; Choi YJ; Wu F; Lou YJ; Ying HZ; Yu CH; Wu QF J Ethnopharmacol; 2025 Jan; 336():118704. PubMed ID: 39182703 [TBL] [Abstract][Full Text] [Related]
54. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. Corbett KS; Flynn B; Foulds KE; Francica JR; Boyoglu-Barnum S; Werner AP; Flach B; O'Connell S; Bock KW; Minai M; Nagata BM; Andersen H; Martinez DR; Noe AT; Douek N; Donaldson MM; Nji NN; Alvarado GS; Edwards DK; Flebbe DR; Lamb E; Doria-Rose NA; Lin BC; Louder MK; O'Dell S; Schmidt SD; Phung E; Chang LA; Yap C; Todd JM; Pessaint L; Van Ry A; Browne S; Greenhouse J; Putman-Taylor T; Strasbaugh A; Campbell TA; Cook A; Dodson A; Steingrebe K; Shi W; Zhang Y; Abiona OM; Wang L; Pegu A; Yang ES; Leung K; Zhou T; Teng IT; Widge A; Gordon I; Novik L; Gillespie RA; Loomis RJ; Moliva JI; Stewart-Jones G; Himansu S; Kong WP; Nason MC; Morabito KM; Ruckwardt TJ; Ledgerwood JE; Gaudinski MR; Kwong PD; Mascola JR; Carfi A; Lewis MG; Baric RS; McDermott A; Moore IN; Sullivan NJ; Roederer M; Seder RA; Graham BS N Engl J Med; 2020 Oct; 383(16):1544-1555. PubMed ID: 32722908 [TBL] [Abstract][Full Text] [Related]
55. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. Yinda CK; Port JR; Bushmaker T; Offei Owusu I; Purushotham JN; Avanzato VA; Fischer RJ; Schulz JE; Holbrook MG; Hebner MJ; Rosenke R; Thomas T; Marzi A; Best SM; de Wit E; Shaia C; van Doremalen N; Munster VJ PLoS Pathog; 2021 Jan; 17(1):e1009195. PubMed ID: 33465158 [TBL] [Abstract][Full Text] [Related]
56. Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. Case JB; Rothlauf PW; Chen RE; Kafai NM; Fox JM; Smith BK; Shrihari S; McCune BT; Harvey IB; Keeler SP; Bloyet LM; Zhao H; Ma M; Adams LJ; Winkler ES; Holtzman MJ; Fremont DH; Whelan SPJ; Diamond MS Cell Host Microbe; 2020 Sep; 28(3):465-474.e4. PubMed ID: 32798445 [TBL] [Abstract][Full Text] [Related]
58. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection. Americo JL; Cotter CA; Earl PL; Liu R; Moss B Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343 [TBL] [Abstract][Full Text] [Related]
59. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine. Deliyannis G; Gherardin NA; Wong CY; Grimley SL; Cooney JP; Redmond SJ; Ellenberg P; Davidson KC; Mordant FL; Smith T; Gillard M; Lopez E; McAuley J; Tan CW; Wang JJ; Zeng W; Littlejohn M; Zhou R; Fuk-Woo Chan J; Chen ZW; Hartwig AE; Bowen R; Mackenzie JM; Vincan E; Torresi J; Kedzierska K; Pouton CW; Gordon TP; Wang LF; Kent SJ; Wheatley AK; Lewin SR; Subbarao K; Chung AW; Pellegrini M; Munro T; Nolan T; Rockman S; Jackson DC; Purcell DFJ; Godfrey DI EBioMedicine; 2023 Jun; 92():104574. PubMed ID: 37148585 [TBL] [Abstract][Full Text] [Related]
60. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection. Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB Front Immunol; 2022; 13():811430. PubMed ID: 35250984 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]